Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESENTATION - Sanara MedTech Inc. | smti_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): February 23, 2021
|
SANARA MEDTECH INC.
|
|
(Exact
name of registrant as specified in its charter)
|
|
Texas
|
001-39678
|
59-2219994
|
|
(State
or other jurisdiction of
|
(Commission File
Number)
|
(IRS
Employer
|
|
incorporation)
|
|
Identification
No.)
|
|
|
|
|
|
1200 Summit Avenue, Suite 414
Fort Worth, Texas
|
|
76102
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (817) 529-2300
(Former
name or former address, if changed since last report)
Not Applicable
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common
Stock, $0.001 par value
|
|
SMTI
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth
company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure.
Sanara
MedTech Inc. (the “Company”) is furnishing a copy of an
investor presentation (the “Presentation”) that the
Company intends to use, in whole or in part, in one or more
meetings with investors. A copy of the Presentation is furnished as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
by reference herein.
The
information contained in the Presentation is summary information
that is intended to be considered in the context of the
Company’s Securities and Exchange Commission filings and
other public announcements that the Company may make, by press
release or otherwise, from time to time. The Company undertakes no
duty or obligation to publicly update or revise the information
contained in the Presentation, although it may do so from time to
time as its management believes is warranted.
The
information in Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, is being furnished and shall not be deemed
“filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities under that Section. Further, the information in
Item 7.01 of this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed to be incorporated by reference into the
filings of the Company under the Securities Act of 1933, as
amended. Item 7.01 of this Current Report on Form 8-K will not be
deemed an admission as to the materiality of any information in
this Current Report on Form 8-K that is required to be disclosed
solely by Regulation FD.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No.
|
|
Description
|
|
|
Investor
Presentation (furnished pursuant to Item 7.01).
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Date:
|
February 23, 2021
|
|
|
|
|
|
|
|
|
|
|
Sanara MedTech Inc.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/
Michael D.
McNeil
|
|
|
|
|
Name:
Michael D. McNeil
|
|
|
|
|
Title:
Chief Financial Officer
|